State-of-the art therapy for gastrointestinal stromal tumors

Cancer Investigation

Volumn 23, Issue 3, 2005, Pages 274-280

  Blanke, Charles D ^a   Corless, Christopher L ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

Gastrointestinal stromal tumor; GIST; Imatinib mesylate; Targeted therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IMATINIB; MITOMYCIN; PACLITAXEL; PROTEIN TYROSINE KINASE; TAXANE DERIVATIVE; TRABECTEDIN;

ADVANCED CANCER; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; DISEASE COURSE; DRUG EFFICACY; EARLY DIAGNOSIS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MOLECULAR MODEL; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; SYSTEMIC THERAPY; TARGET CELL DESTRUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS;

EID: 20044362947     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200055972     Document Type: Review

References (42)

1. Fletcher, C.D.M.; Berman, J.J.; Corless, C.L.; Gorstein, F.; Lasota, J.; Longley, B.J.; Miettinen, M.; O'Leary, T.J.; Remotti, H.; Rubin, B.P.; Shmookler, B.; Sobin, L.H.; Weiss, S.W. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol. 2002, 33 (5), 459-465.
2. Bauer, S.; Corless, C.L.; Heinrich, M.C.; Dirsch, O.; Antoch, G.; Kanja, J.; Seeber, S.; Schutte, J. Response to Imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother. Pharmacol. 2003, 51 (3), 261-265.
3. Plaat, B.E.C.; Hollema, H.; Molenaar, W.M.; Broers, G.H.T.; Pijpe, J.; Mastik, M.F.; Hoekstra, H.J.; van den Berg, E.; Scheper, R.J.; van der Graaf, W.T.A. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins. J. Clin. Oncol. 2000, 18 (18), 3211-3220.
4. Duensing, A.; Medeiros, F.; Joseph, N.E.; McConarty, B.; Yu, L.K.; Liu, C.; Singer, S.; Fletcher, C.D.M.; Demetri, G.D.; Fletcher, J.A. Oncogenic KIT signaling in gastrointestinal stromal tumors (GISTs). Proc. Am. Assoc. Cancer Res. 2003, 44, 1114.
5. Kindblom, L.G. In Gastrointestinal Stromal Tumors: Diagnosis, Epidemiology, Prognosis, Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 2003; 2003.
6. Miettinen, M.; El-Rifai, W.; Sobin, L.H.; Lasota, J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors:, a review. Human Pathol. 2002, 33 (5), 478-483.
7. DeMatteo, R.P.; Lewis, J.J.; Leung, D.; Mudan, S.S.; Woodruff, J.M.; Brennan, M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 2000, 231 (1), 51-58.
8. DeMatteo, R.P.; Maki, R.G.; Antonescu, C.; Brennan, M.F. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr. Probl. Surg. 2003, 40 (3), 144-193.
9. Roberts, J.P.; Eisenberg, B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur. J. Cancer 2002, 38 (Suppl 5), S37-S38.
10. Langer, C.; Gunawan, B.; Schuler, P.; Huber, W.; Fuzesi, L.; Becker, H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumors. Br. J. Surg. 2003, 90 (3), 332-339.
11. Ng, E.H.; Pollock, R.E.; Munsell, M.F. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas: implications for surgical management and staging. Ann. Surg. 1992, 215, 68-77.
12. Mudan, S.S.; Conlon, K.C.; Woodruff, J.M.; Lewis, J.J.; Brennan, M.F. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000, 88 (1), 66-74.
13. Matthews, B.D.; Walsh, R.M.; Kercher, K.W.; Sing, R.F.; Pratt, B.L.; Answini, G.A.; Henifor, B.T. Laparoscopic vs. open resection of gastric stromal tumors. Surg. Endosc. 2002, 16 (5), 803-807.
14. Gunter, E.; Lingenfelser, T.; Eitelbach, F.; Muller, H.; Ell, C. EUS-guided ethanol injection for treatment of a GI stromal tumor. Gastrointest. Endosc. 2003, 57(1), 113-115.
15. Kojima, T.; Takahashi, H.; Parra-Blanco, A.; Kohsen, K.; Fujita, R. Diagnosis of submucosal tumor of the upper GI tract by endoscopic resection. Gastrointest. Endosc. 1999, 50 (4), 516-522.
16. Mavligit, G.M.; Zukwiski, A.A.; Ellis, L.M.; Chuang, V.P.; Wallace, S. Gastrointestinal leiomyosarcoma metastatic to the liver: durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer 1995, 75 (8), 2083-2088.
17. Edmonson, J.H.; Marks, R.S.; Buckner, J.C.; Mahoney, M.R. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Investig. 2002, 20, 605-612.
18. Frustaci, S.; Foladore, S.; Buonadonna, A.; De Paoli, A.; Crivellari, D.; Carbone, A.; Sorio, R.; Morassut, S.; Monfardini, S. Epirubicin and ifosfamide in advanced soft tissue sarcomas. Ann. Oncol. 1993, 4 (8), 669-672.
19. Patel, S.R.; Gandhi, V.; Jenkins, J.; Papadopolous, N.; Burgess, M.A.; Plager, C.; Plunkett, W.; Benjamin, R.S. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J. Clin. Oncol. 2001, 19 (15), 3483-3489.
20. Balcerzak, S.P.; Benedetti, J.; Weiss, G.R.; Natale, R.B. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. Cancer 1995, 76(11), 2248-2252.
21. Verweij, J.; Lee, S.M.; Ruka, W.; Buesa, J.; Coleman, R.; van Hoessel, R.; Seynaeve, C.; de Paola, M.; van Glabbeke, D.; Tonelli, I.R. Randomized phase II study of docetaxel versus doxorubicin in first-and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J. Clin. Oncol. 2000, 18 (10), 2081-2086.
22. Blair, S.C.; Zalupski, M.M.; Baker, L.H. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am. J. Clin. Oncol. 1994, 17, 480-484.
23. Elias, A.; Ryan, L.; Sulkes, A.; Collins, J.; Aisner, J.; Antman, K.H. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J. Clin. Oncol. 1989, 7, 1208-1216.
24. Zalupski, M.; Metch, B.; Balcerzak, S.; Fletcher, W.S.; Chapman, R.; Bonnet, J.D.; Weiss, G.R.; Ryan, J.; Benjamin, R.S.; Baker, L.H. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a southwest oncology group study. J. Natl. Cancer Inst. 1991, 83 (13), 926-932.
25. Ryan, D.P.; Puchalski, T.; Supko, J.G.; Harmon, D.; Maki, R.; Garcia-Carbonero, R.; Kuhlman, C.; Winnkelman, J.; Merriam, P.; Quigley, T.; Jimeno, J.; Manola, J.; Demetri, G.D. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 2002, 7, 531-538.
26. DePas, T.; Casali, P.G.; Toma, S.; Romanini, A.; Massidda, B.; Comandone, A.; Labianca, R.; Massacesi, C.; Tucci, A.; Antimi, M.; Biasco, G.; Aglietta, M.; Apice, G.; deBraud, F. Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? Oncology 2003, 64, 186-188.
27. Eilber, F.C.; Rosen, G.; Forscher, C.; Nelson, D.J.; Dorey, F.J.; Eilber, F.R. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann. Surg. Oncol. 1999, 6, 645-650.
28. Heinrich, M.C.; Blanke, C.D.; Druker, B.J.; Corless, C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 2002, 20 (6), 1692-1703.
29. Mauro, M.J.; O'Dwyer, M.; Heinrich, M.C.; Druker, B.J. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 2002, 20 (1), 325-334.
30. Joensuu, H.; Roberts, P.J.; Sarlomo-Rikala, M.; Andersson, L.C.; Tervahartiala, P.; Tuveson, D.; Silberman, S.L.; Capdeville, R.; Dimitrijevic, S.; Druker, B.; Demetri, G.D. Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001, 344 (14), 1052-1056.
31. van Oosterom, A.T.; Judson, I.R.; Verweij, J.; Stroobants, S.; Dumez, H.; de Paola, E.D.; Sciot, R.; Van Glabbeke, M.; Dimitrijevic, S.; Nielsen, O.S. Update of phase I study of Imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 2002, 38 (Suppl 5), S83-S87.
32. Demetri, G.D.; von Mehren, M.; Blanke, C.D.; van den Abbeele, A.D.; Eisenberg, B.; Roberts, P.J.; Heinrich, M.C.; Tuveson, D.A.; Singer, S.; Janicek, M.; Fletcher, J.A.; Silverman, S.G.; Silberman, S.L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B.J.; Corless, C.; Fletcher, C.D.M.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002, 347 (7), 472-480.
33. von Mehren, M.; Blanke, C.D.; Joensuu, H.; Heinrich, M.C.; Roberts, P.; Eisenberg, B.; Silberman, S.; Dimitrijevic, S.; Kiese, B.; Fletcher, J.; Fletcher, C.; Demetri, G.D. High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors. Proc. Am. Soc. Clin. Oncol. 2002, 21 (1608), 403a.
34. Verweij, J.; van Oosterom, A.; Blay, J.Y.; Judson, I.; Rodenhuis, S.; van der Graaf, W.; Radford, J.; Le Cesne, A.; Hogendoorn, P.C.W.; di Paola, E.D.; Brown, M.; Nielsen, O.S. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC soft tissue and bone sarcoma group phase II study. Eur. J. Cancer 2003, 39 (14), 2006-2011.
35. Benjamin, R.S.; Rankin, C.; Fletcher, C.; Blanke, C.; von Mehren, M.; Maki, R.; Bramwell, V.; Baker, L.; Borden, E.; Demetri, G.D. Phase III dose-randomized study of Imatinib mesylate (STI 571) for GIST: intergroup S0033 early results. Proc. Am. Soc. Clin. Oncol. 2003, 22 (3271), 814.
36. Verweij, J.; Casali, P.G.; Zalcberg, J.; Le Cesne, A.; Reichard, P.; Blay, J.Y.; Issels, R.D.; Van Glabbeke, M.; Di Paola, E.D.; Judson, I.R. Early efficacy comparison of two doses of Imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc. Am. Soc. Clin. Oncol. 2003, 22 (3272), 814.
37. Heinrich, M.C.; Corless, C.L.; von Mehren, M.; Joensuu, H.; Demetri, G.D.; Blanke, C.D.; Dimitrijevic, S.; Kiese, B.; Fletcher, C.D.M.; Fletcher, J.A. PDGFRA and KIT mutations correlate with the clinical responses to Imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST). Proc. Am. Soc. Clin. Oncol. 2003, 22 (3274), 815.
38. Fletcher, J.A.; Corless, C.L.; Dimitrijevic, S.; von Mehren, M.; Eisenberg, B.; Joensuu, H.; Fletcher, C.D.M.; Blanke, C.D.; Demetri, G.D.; Heinrich, M.C. Mechanisms of resistance to Imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc. Am. Soc. Clin. Oncol. 2003, 22 (3275), 815.
39. Demetri, G.D.; George, S.; Heinrich, M.C.; Fletcher, J.A.; Fletcher, C.D.M.; Desai, J.; Cohen, D.P.; Scigalla, P.; Cherrington, J.M.; van den Abbeele, A.D. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc. Am. Soc. Clin. Oncol. 2003, 22 (3273), 814.
40. Nilsson, B.E.; Bumming, P.; Meis-Kindblom, J.M.; Kindblom, L.G.; Engstrom, K.; Wangberg, B.; Jansson, S.; Ahlman, H. Treatment of gastrointestinal stromal tumors (GISTs) with Imatinib in neoadjuvant, adjuvant and palliative settings, a centre-based study of 17 patients. Proc. Am. Soc. Clin. Oncol. 2003, 22 (3337), 830.
41. http://www.acosog.org
42. http://www.RTOG.org